US Edition
Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research - BioTuesdays
Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025. In this role, Mr. DeGeeter will lead equity research coverage of oncology, infectious disease, and cell therapy companies, with a focus on businesses with market capitalizations ranging from $50 million to $5 billion. Prior to rejoining Ladenburg Thalmann, he was an analyst at Oppenheimer & Co., wh…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
